Evidence map›Paper›PMID 42834166›Full record

ArticleNature cell biology2026

Global and specific mechanisms stimulate mistranslation in cancer.

Demi Wernaart, Amos Fumagalli, Mrittika Adhikary, Xiaodong Feng, Olaf Geintzer, Edwin S Kyei-Baffour, Onno B Bleijerveld, Liesbeth Hoekman, Ceri Zwart, Alexander Fish and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Demi Wernaart *Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Amos Fumagalli *Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0009-0005-6726-1752
Mrittika AdhikaryDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Xiaodong FengDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-0928-1932
Olaf GeintzerDepartment of Physical Biochemistry, Max Planck Institute for Multidisciplinary Sciences, Gottingen, Germany.ORCID http://orcid.org/0000-0003-4543-8455
Edwin S Kyei-BaffourDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Onno B BleijerveldNKI Proteomics Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-9395-2347
Liesbeth HoekmanNKI Proteomics Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-3552-6390
Ceri ZwartNKI Proteomics Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Alexander FishDivision of Biochemistry, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Lisanne GiebelDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Artur BuryloDivision of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Natalie ProostPreclinical Intervention Unit and Pharmacology Unit of the Mouse Clinic for Cancer and Ageing (MCCA), The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Pierre-René KörnerDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Ferhat AlkanDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Chao YangDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Janne BrouwerDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Cecilia Anna HenriksenDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Eric WesthofInstitut de biologie moléculaire et cellulaire du CNRS, Université de Strasbourg, Strasbourg, France.ORCID http://orcid.org/0000-0002-6172-5422
Julien ChampagneDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-8460-858X
Olaf van TellingenDivision of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-1037-6269
Marina RodninaDepartment of Physical Biochemistry, Max Planck Institute for Multidisciplinary Sciences, Gottingen, Germany.
Reuven AgamiDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands. r.agami@nki.nl.ORCID http://orcid.org/0000-0002-2848-2473

Funding

EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) ERC-2023-ADG-101141245KWF Kankerbestrijding (Dutch Cancer Society) 13647KWF Kankerbestrijding (Dutch Cancer Society) 15986
6 · The paper itself

Abstract

Tryptophan codon-specific mistranslation, in the form of ribosomal frameshifting and tryptophan-to-phenylalanine (W > F) codon reassignments (substitutants), is induced in cancer cells by the limiting level of tryptophan imposed by anti-tumour immunity. While the oncogenic mitogen-activated protein kinase pathway drives frameshifting, whether substitutants are genetically regulated remains unknown. Here we screened for genes that control W > F substitutants following interferon-γ-mediated tryptophan shortage. This screen identified ADAR1, an enzyme that converts adenosine to inosine in double-stranded RNA molecules, and FTSJ1, an enzyme that 2'-O-methylates the anticodon region of several tRNAs. We demonstrate that ADAR1 sustains expression of key players in the ribosome quality control pathway, which in turn is essential for mistranslation events. FTSJ1, in contrast, specifically drives W > F mistranslation by methylation of tRNA

Identifiers

PMID42834166

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.